Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

DISCONTINUED OPERATIONS AND DECONSOLIDATION OF TRICHOME - Disclosure of results of discontinued operations (Details)

v3.23.1
DISCONTINUED OPERATIONS AND DECONSOLIDATION OF TRICHOME - Disclosure of results of discontinued operations (Details) - CAD ($)
$ in Thousands
 12 Months Ended
Nov. 06, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of analysis of single amount of discontinued operations [line items]        
Revenues   $ 54,335 $ 34,053 [1] $ 15,890
Cost of revenues   43,044 25,458 [1] 7,081
Gross profit   11,291 8,595 [1] 8,809
Fair value adjustments:        
Unrealized change in fair value of biological assets   (315) 6,308 [1] 11,781
Realized fair value adjustments on inventory sold in the year   (1,814) (8,570) [1] (10,122)
Total fair value adjustments   (2,129) (2,262) [1] 1,659
Gross profit after fair value adjustments   9,162 6,333 [1] 10,468
General and administrative expenses   21,460 17,221 [1] 11,549
Selling and marketing expenses   11,473 6,725 [1] 3,782
Restructuring expenses   4,383 0 [1] 0
Share-based compensation   2,637 5,422 [1] 3,382
Total operating expenses   39,953 29,368 [1] 18,713
Operating loss   (30,791) (23,035) [1] (8,245)
Finance expenses, net   4,731 22,871 [1] (20,227)
Loss before income taxes   (26,060) (164) [1] (28,472)
Income tax expense (benefit)   (1,138) 500 [1] 262
Net loss from discontinued operations, net of tax   (166,379) (17,854) [1] $ 0
Discontinued operations [member]        
Disclosure of analysis of single amount of discontinued operations [line items]        
Revenues $ 28,171   20,247  
Cost of revenues 24,227   16,960  
Gross profit 3,944   3,287  
Fair value adjustments:        
Unrealized change in fair value of biological assets 399   902  
Realized fair value adjustments on inventory sold in the year (2,528) $ (2,528) (226)  
Total fair value adjustments (2,129)   676  
Gross profit after fair value adjustments 1,815   3,963  
General and administrative expenses 38,464   14,998  
Selling and marketing expenses 4,912   2,270  
Restructuring expenses 4,506   0  
Share-based compensation 1,130   2,049  
Impairment of goodwill, intangible assets, right-of-use assets and fixed assets 115,112   0  
Total operating expenses 164,124   19,317  
Operating loss (162,309)   (15,354)  
Finance expenses, net (5,264)   (2,495)  
Loss before income taxes (167,573)   (17,849)  
Income tax expense (benefit) (1,194)   5  
Net loss from discontinued operations, net of tax $ (166,379)   $ (17,854)  
[1] Reclassified in respect of discontinued operations - see Note 24.